<DOC>
	<DOCNO>NCT01994291</DOCNO>
	<brief_summary>The study hypothesis test administration CCR2/5 antagonist potential effective current treatment option subject diabetic macular edema . The current treatment option subject injection directly eye , CCR2/5 antagonist would oral drug potential effective . This CCR2/5 antagonist also broad anti-inflammatory potential might able provide alternative mechanism treat Diabetic Macular Edema .</brief_summary>
	<brief_title>A Phase 2 , Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema</brief_title>
	<detailed_description>Study recruitment stop April 9 , 2015 . This decision take business reason due change prioritization drug development portfolio . This decision result evolve safety , efficacy issue change risk : benefit assessment product regulatory interaction .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients Diabetes Mellitus ( Type 1 Type 2 ) Showing Diabetic Macular Edema Eye Reduced visual acuity result retinal thicken Female subject nonchildbearing potential â‰¥18 year male subject great equal 18 year . A subject childbearing potential , opinion investigator , he/she biologically capable child sexually active . Female subject childbearing potential must meet least one follow criterion : Have undergone document hysterectomy and/or bilateral oophorectomy ; Have medically confirm ovarian failure ; Achieved postmenopausal status , define : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; serum follicle stimulate hormone ( FSH ) level within laboratory 's reference range postmenopausal female . Severe Impaired Renal Function Any intraocular condition previous surgery either eye would likely require medical surgical intervention study duration allow progress untreated 16 week study duration , would likely contribute reduction visual acuity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chemokine Antagonist</keyword>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Anti-VEGF</keyword>
</DOC>